ImmuneSensor Therapeutics Receives Orphan Drug and Rare Pediatric Disease Designations from the U.S. FDA for cGAS Inhibitor Drug Candidate, IMSB301, for the Treatment of Aicardi Goutières Syndrome (AGS) Company is evaluating IMSB301 in a Phase 1 clinical trial in healthy volunteers and plans to move rapidly into Phase 1b/2 clinical studies in patients with AGS, lupus and other cGAS-driven diseases ...

ImmuneSensor Therapeutics Initiates Dosing in Phase 1 Clinical Trial of Lead cGAS Inhibitor Drug Candidate, IMSB301 DALLAS, Oct. 08, 2024 (GLOBE NEWSWIRE) -- ImmuneSensor Therapeutics, a clinical-stage biotherapeutics company focused on the development of first- and best-in-class inhibitors and agonists targeting...

ImmuneSensor Therapeutics Granted New U.S. Patent for its Oral cGAS Inhibitors Composition and methods patent granted claims covering compounds for treating broad range of inflammatory and autoimmune diseases and built on foundational intellectual property for the discovery of...

ImmuneSensor Therapeutics Receives Clearance from Australian Regulators to Initiate a First-in-Human Phase 1 Clinical Trial of cGAS inhibitor Drug Candidate, IMSB301 Novel, oral IMSB301 is a potent cGAS inhibitor designed to block signaling through a central pathway that drives diverse inflammatory and autoimmune diseases Company expects to initiate its Phase 1...